Most Recent Articles by Neal Shore, MD, FACS
CTA Advisory Board member, Neal Shore, MD, puts CHAARTED trial results into context.
ChemotherapyAdvisor.com Editorial Board Recommends High-Impact Abstracts from the 2013 Genitourinary Cancers SymposiumFeb 13, 2013
Dr. Neal Shore, MD, FACS, of Atlantic Urology Clinics shares his list of recommended abstracts that will be presented at the 2013 Genitourinary Cancers Symposium.
In this article, Advisory Board member Neal Shore, MD, FACS, discusses barriers to clinicians recommending active surveillance for men with low-risk prostate cancer.
Although there are new therapies for M1CRPC patients and others pending, ideal sequencing regimen is still not certain.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Massage and Cancer
- Pembrolizumab May Lead to Favorable Long-Term Outcomes in Head and Neck Cancer
- Biomarker-Based Blood Test May Extend Reach of CT Screening for Certain Lung Cancers
- Next-Generation Sequencing Adds Value by Detecting More Mutations Than Polymerase Chain Reaction in Melanoma
- Tucatinib May Be A Safe, Novel Treatment for ERBB2/HER2-Positive Breast Cancer